All News
Filter News
Found 808,645 articles
-
Inovedis Announces First Patients Treated with the SINEFIX™ Rotator Cuff Repair System
12/13/2023
Inovedis GmbH today announced that the first two patients were treated with the SINEFIX™ Rotator Cuff Repair System as part of a pre-market clinical study in Tübingen, Germany.
-
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
12/13/2023
Paratek Pharmaceuticals, Inc. today announced that China’s National Healthcare Security Administration (NHSA) has added the oral formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia.
-
Veranex Acquires Leading Preclinical Services Provider T3 Labs
12/13/2023
Veranex today announced that it has acquired T3 Labs, a highly reputable preclinical laboratory located in Atlanta, Georgia.
-
NeuroQure Acquires Patents to Detect Autism in Newborns with a Skin Sample
12/13/2023
NeuroQure, a pioneering biotech startup specializing in gene therapy for neurocognitive disorders, has reached a pivotal milestone in the development of its first commercial product.
-
Xpan secures FDA 510(k) clearance and announces successful completion of initial human clinical cases in the United States
12/13/2023
Xpan Inc., a medical device company focused on minimally invasive surgical innovation, is proud to announce 510(k) clearance from the U.S. Food & Drug Administration for the XpanTM Universal Trocar System, and successful completion of initial clinical procedures in the United States.
-
Introducing Neurolux™: Revolutionizing Relief for Migraine and Photophobia Sufferers with a Dual-Pair Solution
12/13/2023
Value Eyecare Network, a pioneer in innovative eyewear solutions, is thrilled to announce the launch of Neurolux™, a groundbreaking product designed to bring comfort and relief to individuals suffering from migraines, photophobia (light sensitivity), and blepharospasm.
-
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
12/13/2023
Propanc Biopharma, Inc. today announced that the Company’s joint researcher, Mrs. Belén Toledo Cutillas, has commenced an internship at the Cancer Center Amsterdam – vUMC (University Medical Centers).
-
Rapid Medical™ Announces Japanese Approval and Exclusive Partnership With Kaneka for TIGERTRIEVER–The World’s Only Adjustable Thrombectomy Device
12/13/2023
Rapid Medical™, a leading developer of advanced neurovascular devices, announced Japanese approval for its TIGERTRIEVER revascularization device.
-
Hedonia: Novel Approach Finds Dramatic Improvement in Depression Scores in Robust Clinical Trial
12/13/2023
Patients with depression experienced a clinically significant reduction in symptoms after using a research-based mobile application for just eight weeks, according to new findings from Hedonia’s clinical trial run at Massachusetts General Hospital (MGH).
-
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
12/13/2023
CytoSorbents Corporation today announces the closing of its previously announced registered direct offering for the sale by the Company directly to investors of an aggregate of 7,733,090 shares of registered common stock.
-
UroMems Reaches Significant Milestone: Successful Results in Clinical Feasibility Study of UroActive™ Smart Implant for Stress Urinary Incontinence Treatment
12/13/2023
UroMems announced today it has reached a significant milestone: the complete treatment cohort in the first-of-its-kind clinical feasibility study has successfully reached the six-month primary endpoints.
-
United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
12/13/2023
United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger.
-
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
12/13/2023
Kyverna Therapeutics, Inc. (Kyverna) today announced it received fast track designation by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of myasthenia gravis (MG).
-
Almaden Genomics’ g.nome™ Further Enhances Single-Cell Analysis
12/13/2023
Almaden Genomics has incorporated an end-to-end solution into g.nome™ to process, analyze, and visualize single-cell RNAseq data.
-
Ginkgo Bioworks Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for Treating HIV and Malaria
12/13/2023
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has received a grant from the Bill & Melinda Gates Foundation to develop a novel cell-based technology for improving protein therapeutics delivery for patients in low- and middle-income countries (LMICs).
-
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
12/13/2023
Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial.
-
Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks
12/13/2023
Lucem Health™, a leader in AI-driven early disease detection solutions, announced today the release of Reveal for Stroke, an innovative solution designed to identify patients with undocumented atrial fibrillation (AFib) and higher risk of AFib-related strokes
-
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154
12/13/2023
Shattuck Labs, Inc. today announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.
-
The Orthopaedic Research Society to Celebrate 70 Years at Their 2024 ORS Annual Meeting
12/13/2023
Orthopaedic disorders are lifechanging ailments that touch every one of us, whether personally, or through the challenging experiences of family members or friends.
-
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
12/13/2023
Centogene N.V. today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study , being conducted to advance the genetic understanding of frontotemporal dementia (FTD).